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with 48.6% (n = 31,717) and 50.0% (n = 32,614) for the
50-mg and 100-mg doses, respectively. Ninety-four
percent of prescriptions were ﬁlled with six tablets, and
only 2% of prescriptions (n = 1309) exceeded the quan-
tity vs. time limit. Members paid an average copay of $13
per prescription. CONCLUSIONS: This estimate of
PMPM cost falls within the range previously reported in
the literature. In comparison with PMPM costs reported
for other drug classes, such as proton pump inhibitors or
cyclooxygenase-2 inhibitors, the amount spent on silde-
naﬁl citrate is considerably lower and of lesser concern to
the pharmacy budget.
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OBJECTIVES: Managed care organizations (MCOs)
have traditionally used various types of formulary access
to control cost, with varied success. In this case study, we
determined the actual economic impact of adding silde-
naﬁl citrate to the formulary of a large national MCO by
types of access status. METHODS: Claims data for silde-
naﬁl prescriptions were analyzed for the 12-month period
from August 2001 through July 2002 for this MCO 
and for 7 of its regional areas. Per member per month
(PMPM) costs of sildenaﬁl coverage were calculated by
various formulary status at both the regional and national
levels. RESULTS: The MCO did not require prior autho-
rization for sildenaﬁl prescriptions but did impose restric-
tions on the number of sildenaﬁl tablets per monthly
prescription cycle. The MCO used open, closed, and
incented formularies to control access to sildenaﬁl. Mean
number of sildenaﬁl tablets/month varied from 4.9 to 
6.7 tablets. PMPM costs of sildenaﬁl coverage for the
regional areas were $0.07, $0.11, $0.11, $0.14, $0.15,
$0.15, and $0.18. Type of formulary did not fully explain
variance in costs between regions. In 5 of the 7 areas in
which most patients were covered under an incented for-
mulary, PMPM costs of sildenaﬁl coverage ranged from
$0.11 to $0.15. In the 2 regions with the greatest per-
centage of patients covered under a closed formulary
plan, PMPM costs of sildenaﬁl coverage were $0.07
(44% closed) and $0.15 (54% closed). Whereas in the 3
regions with the most patients covered under an open for-
mulary, PMPM costs of sildenaﬁl coverage were $0.11
(27% open), $0.14 (30% open), and $0.15 (30% open).
CONCLUSIONS: PMPM costs did not vary substan-
tially, regardless of different types of formulary access.
Moreover, in line with ﬁndings from local and employer-
based healthcare plans, addition of sildenaﬁl coverage by
this large MCO resulted in lower than expected PMPM
costs.
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OBJECTIVE: The perception persists among employers
and beneﬁt managers that the addition of sildenaﬁl citrate
adds signiﬁcant cost to their prescription plans. A Disease
Therapy Evaluation is a focused analysis of a drug’s per-
formance in a target patient population and provides
healthcare managers with information that may lead to
better decisions for the individual patient as well as the
healthcare organization. The analysis presented here eval-
uates the per member per month (PMPM) cost of silde-
naﬁl without restriction limits on the quantity of tablets
dispensed. METHODS: This retrospective review covered
all sildenaﬁl claims of employees obtained from prescrip-
tion beneﬁt managers. Prescription claims were obtained
for a 6-month interval from December 1999 to May 2000
and imported into an Access database for abstraction of
required data. RESULTS: Data were combined from 4
prescription plans (3 from the Midwest, 1 from the West
Coast) with 361,237 members overall. There were 3477
sildenaﬁl claims in the 6-month period, made by 1493
patients (representing 0.4% of all members). Most of the
prescriptions were for the 50-mg (range for 4 plans,
45%–62%) and 100-mg doses (37%–65%) of sildenaﬁl,
with 1% to 2.5% for the 25-mg dose. On average, 6 to
11 tablets were dispensed at a time, with a range from 1
to 100 tablets. The average cost per prescription varied
from a low end of $50 to a high end of $88; the PMPM
cost ranged from $0.03 to $0.24. CONCLUSIONS: The
actual PMPM cost is markedly lower than the expected
projections, despite the fact that no quantity limits were
imposed. The costs shown here do not take into account
any rebates or other contracting beneﬁts. Thus, employ-
ers may wish to consider the addition of sildenaﬁl to their
beneﬁt package, as it may increase employee satisfaction
without a large impact on the budget.
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OBJECTIVE: Few studies have assessed the effect of erec-
tile dysfunction (ED) treatment for psychological adjust-
ment. This study assessed the impact of ED therapy 
on psychological functioning at baseline and 12-month
follow-up using a battery of 10 standard psychological
measures previously used in ED research. METHODS:
Using an observational ED disease registry, clinical,
sociodemographic psychological, and HRQoL informa-
tion was collected at baseline prior to treatment and at 3,
6 and 12 months later. Psychological measures included
the Beck Depression Inventory, a Life Satisfaction ques-
tion, Marital Happiness item from the Locke Wallace
Marital Adjustment Test, Mental Health Index 5, SF 36
Vitality scale, SOS 10 (a measure of general psychologi-
cal health), State Trait Anxiety measure, and three MOS
subscales (Positive Affect, Belonging/Loneliness, Marital
Functioning). Only men who reported undergoing ED
treatment were included in this analysis sub-sample.
Patients were classiﬁed as treatment responders based on
improvements in IIEF scores. Group means at baseline
and 12-months and change between timepoints were
compared using t-tests. RESULTS: The cohort consisted
of 89 patients. 40 (45%) responded to therapy by the IIEF
criteria. At one year, responders reported better psycho-
logical functioning on 7 measures, with differences being
signiﬁcant (p < .05) on Life Satisfaction, Marital Happi-
ness, Positive Affect, and SOS 10. Responders reported
signiﬁcant improvement (p < .05) from baseline on 3 mea-
sures (Life Satisfaction, Positive Affect, and SOS 10) and
a signiﬁcant decline on one (SF 36 Vitality). CONCLU-
SIONS: Diagnosing and successfully treating ED has a
signiﬁcant impact on patient psychological functioning.
These results should encourage providers to actively diag-
nose and treat ED. Data from this study show that men
who fail primary therapy for ED should be offered sec-
ondary treatment, as many men in this study who failed
prior therapies still reported improved psychological
functioning when they began an effective secondary 
treatment.
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OBJECTIVE: Response to erectile dysfunction (ED) treat-
ment has typically been reported over a three-month
period in a number of pharmaceutical trials. Little is
known about the factors associated with response to
treatment over a longer period. The current study exam-
ines predictors associated with response to treatment at
12 months in a group of men enrolled in an ED disease
registry study. METHODS: Clinical information was col-
lected at baseline and HRQOL data was collected at base-
line, 3, 6, and 12-months. Eighty-nine men reported
receiving ED treatment while enrolled in the study and
completed the 12-month HRQOL questionnaire. Scores
on the IIEF erectile functioning scale at baseline and 
12-months were compared. Men who reported a 4-point
or greater improvement were considered treatment
responders (N = 40). Forty-nine men were classiﬁed as
non-responders. A multivariate logistic regression model
predicting treatment response at 12 months and control-
ling for age and baseline erectile functioning was speci-
ﬁed. RESULTS: Men who were treatment responders at
the 12-month follow-up were signiﬁcantly more likely at
baseline to have a partner who encourages sex (OR =
4.230, p = .0369), be unmarried (OR = 0.05, p = .0020),
report greater rigidity during sex (OR = 4.814, p = .0288),
and have more frequent morning erections (OR = 4.360,
p = .0432). CONCLUSIONS: Long-term response to ED
treatment is signiﬁcantly associated with baseline erectile
functioning (as measured by frequency of morning erec-
tions and penile rigidity during sex) and the supportive-
ness of a partner. Practitioners can use this information
to guide patient expectations for treatment outcomes and
to recommend other treatment if relationship concerns
are present.
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OBJECTIVE: To evaluate the psychometric properties 
of a new disease speciﬁc instrument, the female sexual
desire proﬁle (FSDP). METHODS: The FSDP is a self-
assessment questionnaire containing eight items that
address the occurrence of sexual desire and sexual recep-
tivity. The study enrolled a total of 174 patients with
hypoactive sexual desire disorder in 5 countries (Canada,
UK, Poland, Hungary and The Netherlands) randomized
to receive either active treatment or placebo. Patients
completed the FSDP on a daily basis during the baseline
and treatment periods. Standard psychometric analyses
were conducted. RESULTS: Conﬁrmatory factor analysis
was undertaken to provide evidence of a single construct
of desire in the FSDP. All FSDP questions loaded onto the
factor in excess of 0.4. Three questions had high loadings
in excess of 0.7 (items 2, 4 and 5). The FSDP had good
internal consistency, 0.72 for the baseline data and 0.86
for the treatment period. There was no indication of item
redundancy. The FSDP scores showed a moderate corre-
lation with desire domain of the Female Sexual Function
Index (FSFI) for the baseline period (0.39) and treatment
